Chib Rahul, Raut Sangram, Fudala Rafal, Chang Aaron, Mummert Mark, Rich Ryan, Gryczynski Zygmunt, Gryczynski Ignacy
Department of Molecular Biology and Immunology, Center for Commercialization of Fluorescence Technologies, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Curr Pharm Biotechnol. 2013;14(4):470-4. doi: 10.2174/13892010113149990222.
Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.
在膀胱癌和前列腺癌患者的尿液中发现透明质酸酶水平升高。因此，透明质酸酶被视为检测这些癌症的重要生物标志物。在本报告中，我们使用基于荧光共振能量转移（FRET）的比率传感方法来检测合成尿液中透明质酸酶的水平。为此，我们使用了一种以荧光素作为供体、罗丹明作为受体标记的透明质酸-FRET探针（透明质酸）。我们通过荧光发射监测不同浓度的透明质酸酶在合成尿液中对我们的透明质酸-FRET探针的消化情况。FRET释放的程度取决于透明质酸酶的浓度。我们的荧光强度结果也得到了时间分辨荧光衰减数据的支持。该检测方法可用于开发一种非侵入性技术，以检测膀胱癌和/或前列腺癌的进展情况。
